article_metadata: Egle Stukaite-Ruibiene Rimvydas Norvilas Vaidas Dirse Sigita Stankeviciene Goda Elizabeta Vaitkeviciene
article_metadata: 10.3389/pore.2022.1610570
article_metadata: Pathol Oncol Res
article_metadata: 2022 Sep 12;28:1610570.
article_metadata: bcr-abl1-like acute lymphoblastic leukemia case report imatinib targeted therapy tyrosine kinase inhibitors
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/36172171/
article_metadata: Antineoplastic Agents / therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
article_metadata: Antineoplastic Agents / therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics Case Reports Adolescent Benzamides Gene Fusion Humans Imatinib Mesylate / therapeutic use Nuclear Pore Complex Proteins / genetics Oncogene Proteins, Fusion / genetics Oncogene Proteins, Fusion / metabolism Piperazines / pharmacology Protein Kinase Inhibitors / pharmacology Protein Kinase Inhibitors / therapeutic use Protein Kinases / genetics Protein Kinases / metabolism Pyrimidines / therapeutic use Antineoplastic Agents Benzamides NUP214 protein, human Nuclear Pore Complex Proteins Oncogene Proteins, Fusion Piperazines Protein Kinase Inhibitors Pyrimidines Imatinib Mesylate Protein Kinases
article_metadata: PMC9510372
article_metadata: 36172171
article_metadata: Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214:: ABL1 Gene Fusion
article_metadata: 2022